The remainder of our business also performed well with some standout performances in areas where new products are making a difference. In Coronary, our Resolute Integrity drug-eluting stent picked up an additional 7 points of share in the U.S. this quarter, nearly tripling our share over the past 2 quarters.In Endovascular, the launch of our Endurant abdominal aortic stent graft in Japan and the release of Endurant II in the U.S. and in Europe are driving strong growth in our aortic business. Across the balance of our CVG portfolio, we continue to see double-digit growth in transcatheter valves, in AF ablation and our peripheral interventional product lines.
Medtronic Management Discusses Q1 2013 Results - Earnings Call Transcript
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.